Sidney H Kennedy

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/162409/sidney-h-kennedy-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

481 papers	28,783 citations	87 h-index	157 g-index
524 ext. papers	33,250 ext. citations	4.8 avg, IF	6.97 L-index

#	Paper	IF	Citations
481	Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report.. *Cerebellum*, **2022**, 1	4.3	
480	Cerebello-limbic functional connectivity patterns in youth at clinical high risk for psychosis.. *Schizophrenia Research*, **2022**, 240, 220-227	3.6	0
479	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders.. *Frontiers in Psychiatry*, **2022**, 13, 816465	5	
478	Habenular Involvement in Response to Subcallosal Cingulate Deep Brain Stimulation for Depression.. *Frontiers in Psychiatry*, **2022**, 13, 810777	5	0
477	"One Degree of Separation": A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19.. *Canadian Journal of Psychiatry*, **2022**, 7067437211070656	4.8	0
476	Psychological and Mental Health Sequelae of Concussion: Prevalence, Treatment Recommendations, Novel Biomarkers, and Diagnostic Challenges **2022**, 131-151		
475	Investigating the Effects of Auditory and Vibrotactile Rhythmic Sensory Stimulation on Depression: An EEG Pilot Study.. *Cureus*, **2022**, 14, e22557	1.2	0
474	Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.. *Brain and Behavior*, **2022**, e2555	3.4	1
473	Beyond Response: Aiming for Quality Remission in Depression.. *Advances in Therapy*, **2022**, 1	4.1	0
472	Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.. *Psychiatry Research*, **2022**, 312, 114557	9.9	
471	Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report.. *Journal of Psychopharmacology*, **2022**, 36, 604-613	4.6	0
470	Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. *Journal of Affective Disorders Reports*, **2022**, 9, 100370	1.4	
469	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. *World Journal of Biological Psychiatry*, **2021**, 22, 483-494	3.8	11
468	A qualitative systematic review of neurocognition in suicide ideators and attempters: Implications for cognitive-based psychotherapeutic interventions. *Neuroscience and Biobehavioral Reviews*, **2021** , 132, 92-109	9	1
467	Stellate Ganglion Block for Psychiatric Disorders: A Systematic Review of the Clinical Research Landscape.. *Chronic Stress*, **2021**, 5, 24705470211055176	3	1
466	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. *NeuroImage: Clinical*, **2021**, 32, 102864	5.3	1
465	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis.. *Psychological Medicine*, **2021**, 51, 2742-2751	6.9	3

464	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. *Bipolar Disorders*, **2021**,	3.8	6
463	Cognition and Its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble D'dépressif Majeur: Une Étude Can-Bind-1.	4.8	
462	Clinical staging for youth at-risk for serious mental illness: A longitudinal perspective. *Microbial Biotechnology*, **2021**, 15, 1188-1196	3.3	2
461	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2021**, 111, 110194	5.5	4
460	Functional imaging in youth at risk for transdiagnostic serious mental illness: Initial results from the PROCAN study. *Microbial Biotechnology*, **2021**, 15, 1276-1291	3.3	0
459	Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. *CNS Drugs*, **2021**, 35, 291-304	6.7	0
458	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. *Pharmacopsychiatry*, **2021**, 54, 225-231	2	1
457	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. *CNS Drugs*, **2021**, 35, 439-450	6.7	1
456	Investigating correlates of athletic identity and sport-related injury outcomes: a scoping review. *BMJ Open*, **2021**, 11, e044199	3	4
455	'Distant socializing,' not 'social distancing' as a public health strategy for COVID-19. *Pathogens and Global Health*, **2021**, 115, 357-364	3.1	3
454	Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report. *Personality and Mental Health*, **2021**, 15, 273-282	3.1	
453	Symptom dimensions of major depression in a large community-based cohort. *Psychological Medicine*, **2021**, 1-8	6.9	0
452	White matter microstructure in youth at risk for serious mental illness: A comparative analysis. *Psychiatry Research - Neuroimaging*, **2021**, 312, 111289	2.9	0
451	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. *PLoS ONE*, **2021**, 16, e0253023	3.7	1
450	Substance use in youth at-risk for serious mental illness. *Microbial Biotechnology*, **2021**, 15, 634-641	3.3	0
449	Probabilistic Mapping of Deep Brain Stimulation: Insights from 15 Years of Therapy. *Annals of Neurology*, **2021**, 89, 426-443	9.4	32
448	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble D'dépressif Majeur. *Canadian Journal of Psychiatry*, **2021**, 66, 113-125	4.8	15
447	Personality and risk for serious mental illness. *Microbial Biotechnology*, **2021**, 15, 133-139	3.3	2

446	Treatment resistant depression **2021**, 33-84		
445	Longitudinal Trends in Medication Treatment for Youth At-Risk for Serious Mental Illness. *Canadian Journal of Psychiatry*, **2021**, 66, 418-420	4.8	
444	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. *Translational Psychiatry*, **2021**, 11, 127	8.6	5
443	Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment. *Depression and Anxiety*, **2021**, 38, 456-467	8.4	7
442	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. *Frontiers in Psychiatry*, **2021**, 12, 617997	5	3
441	Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report. *Communications Biology*, **2021**, 4, 903	6.7	2
440	Exploring brain connectivity changes in major depressive disorder using functional-structural data fusion: A CAN-BIND-1 study. *Human Brain Mapping*, **2021**, 42, 4940-4957	5.9	3
439	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. *Translational Psychiatry*, **2021**, 11, 439	8.6	1
438	Neuron-derived extracellular vesicles enriched from plasma show altered size and miRNA cargo as a function of antidepressant drug response. *Molecular Psychiatry*, **2021**,	15.1	8
437	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16 Weeks of Pharmacotherapy: A CAN-BIND Report. *Cerebral Cortex*, **2021**,	5.1	1
436	Brain age in mood and psychotic disorders: a systematic review and meta-analysis. *Acta Psychiatrica Scandinavica*, **2021**,	6.5	1
435	Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report. *Translational Psychiatry*, **2021**, 11, 469	8.6	
434	Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscape. *Brain Stimulation*, **2021**, 14, 1393-1403	5.1	1
433	Cortisol reactivity to stress predicts behavioral responsivity to reward moderation by sex, depression, and anhedonia. *Journal of Affective Disorders*, **2021**, 293, 1-8	6.6	3
432	Metabolic variables associated with response to cognitive behavioural therapy for depression in females: A Canadian biomarker integration network for depression (CAN-BIND) study. *Journal of Psychiatric Research*, **2021**, 142, 321-327	5.2	0
431	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. *Psychoneuroendocrinology*, **2021**, 132, 105348	5	0
430	A randomized sham controlled comparison of once vs twice-daily intermittent theta burst stimulation in depression: A Canadian rTMS treatment and biomarker network in depression (CARTBIND) study. *Brain Stimulation*, **2021**, 14, 1447-1455	5.1	2
429	Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: A CAN-BIND-1 study report. *Journal of Affective Disorders*, **2021**, 295, 1095-1101	6.6	0

428	Structuro-functional surrogates of response to subcallosal cingulate deep brain stimulation for depression. *Brain*, **2021**,	11.2	8
427	Magnetic Resonance Imaging Sequence Identification Using a Metadata Learning Approach. *Frontiers in Neuroinformatics*, **2021**, 15, 622951	3.9	1
426	Comparative study of the pencil-and-paper and digital formats of the Spanish DARS scale.. *Acta Neuropsychiatrica*, **2021**, 1-21	3.9	
425	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. *Neuropsychopharmacology*, **2020**, 45, 1390-1397	8.7	15
424	White Matter Connectivity in Youth at Risk for Serious Mental Illness: A Longitudinal Analysis. *Psychiatry Research - Neuroimaging*, **2020**, 302, 111106	2.9	0
423	A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. *BMC Psychiatry*, **2020**, 20, 268	4.2	9
422	An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. *NeuroImage: Clinical*, **2020**, 25, 102178	5.3	4
421	Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2020**, 100, 109867	5.5	4
420	Aberrant limbic brain structures in young individuals at risk for mental illness. *Psychiatry and Clinical Neurosciences*, **2020**, 74, 294-302	6.2	3
419	Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disorders. *Psychiatry Research*, **2020**, 288, 112967	9.9	0
418	GPR56/ADGRG1 is associated with response to antidepressant treatment. *Nature Communications*, **2020**, 11, 1635	17.4	18
417	Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression. *Journal of Psychiatry and Neuroscience*, **2020**, 45, 45-54	4.5	13
416	Patient Response Trajectories in Major Depressive Disorder. *Psychopharmacology Bulletin*, **2020**, 50, 8-28	0.9	3
415	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. *Innovations in Clinical Neuroscience*, **2020**, 17, 30-40	1	3
414	Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report. *Journal of Clinical Psychiatry*, **2020**, 81,	4.6	5
413	Dr Uher and Colleagues Reply. *Journal of Clinical Psychiatry*, **2020**, 82,	4.6	1
412	Childhood maltreatment and the clinical characteristics of major depressive disorder in adolescence and adulthood. *Journal of Abnormal Psychology*, **2020**, 129, 469-479	7	8
411	Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial. *Brain Stimulation*, **2020**, 13, 337-340	5.1	10

410	Sleep disturbances in youth at-risk for serious mental illness. *Microbial Biotechnology*, **2020**, 14, 373-378	3.3	9
409	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. *Neuropsychopharmacology*, **2020**, 45, 283-291	8.7	18
408	Collaborating with individuals with lived experience to adapt CANMAT clinical depression guidelines into a patient treatment guide: The CHOICE-D co-design process. *Journal of Evaluation in Clinical Practice*, **2020**, 26, 1259-1269	2.5	2
407	Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. *JAMA Network Open*, **2020**, 3, e1918377	10.4	20
406	Trauma in Youth At-Risk for Serious Mental Illness. *Journal of Nervous and Mental Disease*, **2020**, 208, 70-76	1.8	6
405	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. *International Journal of Neuropsychopharmacology*,	5.8	5
404	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. *Journal of Affective Disorders*, **2020**, 264, 414-424	6.6	3
403	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. *Journal of Affective Disorders*, **2020**, 263, 353-366	6.6	4
402	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. *Human Brain Mapping*, **2020**, 41, 1400-1415	5.9	5
401	Childhood trauma and amygdala nuclei volumes in youth at risk for mental illness. *Psychological Medicine*, **2020**, 1-8	6.9	6
400	Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. *International Clinical Psychopharmacology*, **2020**, 35, 243-253	2.2	6
399	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. *Psychological Medicine*, **2020**, 50, 2536-2547	6.9	6
398	Social and role functioning in youth at risk of serious mental illness. *Microbial Biotechnology*, **2020**, 14, 463-469	3.3	4
397	White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, **2019**, 4, 913-924	3.4	11
396	Clinical staging for youth at-risk for serious mental illness. *Microbial Biotechnology*, **2019**, 13, 1416-1423	3.3	27
395	A Pilot Study Investigating the Effect of Music-Based Intervention on Depression and Anhedonia. *Frontiers in Psychology*, **2019**, 10, 1038	3.4	9
394	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. *NeuroImage*, **2019**, 197, 589-597	7.9	19
393	The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. *World Psychiatry*, **2019**, 18, 183-191	14.4	40

392	The impact of comorbid pain and depression in the United States: results from a nationally representative survey. *Scandinavian Journal of Pain*, **2019**, 19, 319-325	1.9	10
391	Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity - a consensus of the Biomarkers Task Force from the WFSBP. *World Journal of Biological Psychiatry*, **2019**, 20, 340-351	3.8	12
390	Trajectories of Response to Dorsolateral Prefrontal rTMS in Major Depression: A THREE-D Study. *American Journal of Psychiatry*, **2019**, 176, 367-375	11.9	50
389	Association of functioning and quality of life with objective and subjective measures of sleep and biological rhythms in major depressive and bipolar disorder. *Australian and New Zealand Journal of Psychiatry*, **2019**, 53, 683-696	2.6	24
388	Treatment History of Youth At-Risk for Serious Mental Illness. *Canadian Journal of Psychiatry*, **2019**, 64, 145-154	4.8	6
387	Cortical thickness in major depressive disorder: A systematic review and meta-analysis. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2019**, 88, 287-302	5.5	53
386	Integrating digital phenotyping in clinical characterization of individuals with mood disorders. *Neuroscience and Biobehavioral Reviews*, **2019**, 104, 223-230	9	15
385	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. *Journal of Affective Disorders*, **2019**, 257, 765-773	6.6	13
384	The utility of artificial intelligence in suicide risk prediction and the management of suicidal behaviors. *Australian and New Zealand Journal of Psychiatry*, **2019**, 53, 954-964	2.6	28
383	Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. *JAMA Network Open*, **2019**, 2, e1913304	10.4	9
382	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. *Translational Psychiatry*, **2019**, 9, 254	8.6	18
381	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. *Journal of Psychiatry and Neuroscience*, **2019**, 44, 223-236	4.5	22
380	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report. *Journal of Clinical Psychiatry*, **2019**, 80,	4.6	38
379	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. *Journal of Clinical Psychiatry*, **2019**, 80,	4.6	10
378	Gut microbial metabolites in depression: understanding the biochemical mechanisms. *Microbial Cell* , **2019**, 6, 454-481	3.9	75
377	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. *Psychological Medicine*, **2019**, 49, 1629-1638	6.8	14
376	Spanish adaptation of the Dimensional Anhedonia Rating Scale (DARS). *Journal of Affective Disorders*, **2019**, 245, 702-707	6.6	6
375	More data, more answers: picking the optimal antidepressant. *Lancet, The*, **2018**, 391, 1333-1334	40	5

374	Improvements in Health-Related Quality of Life With Electroconvulsive Therapy: A Meta-analysis. *Journal of ECT*, **2018**, 34, 87-94	2	14
373	Presentation and Neurobiology of Anhedonia in Mood Disorders: Commonalities and Distinctions. *Current Psychiatry Reports*, **2018**, 20, 13	9.1	14
372	Anhedonia in depression and schizophrenia: A transdiagnostic challenge. *CNS Neuroscience and Therapeutics*, **2018**, 24, 615-623	6.8	48
371	Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. *Lancet, The*, **2018**, 391, 1683-1692	40	365
370	GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. *Journal of Psychiatric Research*, **2018**, 99, 62-68	5.2	36
369	Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management. *CNS Drugs*, **2018**, 32, 65-74	6.7	24
368	Abnormal Functional Connectivity of Frontopolar Subregions in Treatment-Nonresponsive Major Depressive Disorder. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, **2018**, 3, 337-347	3.4	10
367	Unpacking Major Depressive Disorder: From Classification to Treatment Selection. *Canadian Journal of Psychiatry*, **2018**, 63, 308-313	4.8	7
366	Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. *Human Psychopharmacology*, **2018**, 33, e2646	2.3	2
365	Anhedonia as a Crucial Factor of Depression: Assessment, Neurobiological Underpinnings and Treatment **2018**, 99-112		1
364	Conflict monitoring mechanism at the single-neuron level in the human ventral anterior cingulate cortex. *NeuroImage*, **2018**, 175, 45-55	7.9	9
363	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disorders*, **2018**, 20, 97-170	3.8	639
362	Genome-wide association studies of placebo and duloxetine response in major depressive disorder. *Pharmacogenomics Journal*, **2018**, 18, 406-412	3.5	14
361	Early symptom improvement at 10 sessions as a predictor of rTMS treatment outcome in major depression. *Brain Stimulation*, **2018**, 11, 181-189	5.1	18
360	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. *World Journal of Biological Psychiatry*, **2018**, 19, 330-348	3.8	20
359	Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. *Journal of Affective Disorders*, **2018**, 226, 294-300	6.6	5
358	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. *Focus (American Psychiatric Publishing)*, **2018**, 16, 85-94	1.1	7
357	Youth at-risk for serious mental illness: methods of the PROCAN study. *BMC Psychiatry*, **2018**, 18, 219	4.2	23

356	Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder. *Journal of Affective Disorders*, **2018**, 238, 122-128	6.6	9
355	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. *Journal of Affective Disorders*, **2018**, 227, 542-549	6.6	46
354	Neuroimaging biomarkers as predictors of treatment outcome in Major Depressive Disorder. *Journal of Affective Disorders*, **2018**, 233, 21-35	6.6	88
353	Performance of the biological rhythms interview for assessment in neuropsychiatry: An item response theory and actigraphy analysis. *Journal of Affective Disorders*, **2018**, 225, 54-63	6.6	21
352	Report of the 2016 Mental Health Expert Panel on suicide prevention in the Canadian Armed Forces. *Journal of Military, Veteran and Family Health*, **2018**, 4, 70-89	0.7	7
351	Neurocognitive deficits in a transdiagnostic clinical staging model. *Psychiatry Research*, **2018**, 270, 1137-1142	9.9	9
350	Family functioning in youth at-risk for serious mental illness. *Comprehensive Psychiatry*, **2018**, 87, 17-24	7.3	11
349	Vagus Nerve Stimulation: A Treatment in Evolution. *Cognitive and Behavioral Neurology*, **2018**, 31, 99-100	1.6	
348	Is tetraethyl lead poison affecting contemporary indigenous suicides in Ontario, Canada?. *Psychiatry Research*, **2017**, 251, 253-254	9.9	1
347	Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. *Canadian Journal of Psychiatry*, **2017**, 62, 77-78	4.8	
346	Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series. *Journal of Clinical Psychopharmacology*, **2017**, 37, 464-467	1.7	18
345	Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. *Canadian Journal of Psychiatry*, **2017**, 62, 353-354	4.8	
344	The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis. *Journal of Clinical Psychopharmacology*, **2017**, 37, 412-418	1.7	42
343	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. *Nature Communications*, **2017**, 8, 15497	17.4	93
342	Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response. *International Journal of Neuropsychopharmacology*, **2017**, 20, 619-623	5.8	34
341	A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. *Bipolar Disorders*, **2017**, 19, 198-213	3.8	34
340	A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. *Journal of Affective Disorders*, **2017**, 210, 57-65	6.6	33
339	The Default Mode Network in Healthy Individuals: A Systematic Review and Meta-Analysis. *Brain Connectivity*, **2017**, 7, 25-33	2.7	136

338	Sirukumab: A Potential Treatment for Mood Disorders?. *Advances in Therapy*, **2017**, 34, 78-90	4.1	23
337	Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression. *Scientific Reports*, **2017**, 7, 7473	4.9	15
336	Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. *Journal of Psychopharmacology*, **2017**, 31, 312-319	4.6	9
335	Brexpiprazole in the Treatment of Major Depressive Disorder. *Clinical Medicine Insights Therapeutics* , **2017**, 9, 1179559X1773180	0	3
334	Neurocognitive Predictors of Response in Treatment Resistant Depression to Subcallosal Cingulate Gyrus Deep Brain Stimulation. *Frontiers in Human Neuroscience*, **2017**, 11, 74	3.3	24
333	Recognition and management of antidepressant discontinuation syndrome. *Journal of Psychiatry and Neuroscience*, **2017**, 42, E7-E8	4.5	6
332	Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment. *primary care companion for CNS disorders, The*, **2016**, 18,	1.2	28
331	Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications. *Molecular Neuropsychiatry*, **2016**, 2, 1-14	4.9	42
330	Deep brain stimulation **2016**, 277-293		
329	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. *BMC Psychiatry*, **2016**, 16, 105	4.2	80
328	Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. *European Neuropsychopharmacology*, **2016**, 26, 378-389	1.2	22
327	Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project. *Obesity Research and Clinical Practice*, **2016**, 10, 531-543	5.4	14
326	Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. *American Journal of Psychiatry*, **2016**, 173, 481-90	11.9	28
325	The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. *Therapeutic Advances in Chronic Disease*, **2016**, 7, 153-9	4.9	23
324	Assessing anhedonia in depression: Potentials and pitfalls. *Neuroscience and Biobehavioral Reviews*, **2016**, 65, 21-35	9	214
323	The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. *Innovations in Clinical Neuroscience*, **2016**, 13, 20-31	1	8
322	Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. *CNS Spectrums*, **2016**, 21, 362-366	1.8	18
321	Admixture analysis of age at onset in first episode bipolar disorder. *Journal of Affective Disorders*, **2016**, 201, 88-94	6.6	9

320	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Introduction and Methods. *Canadian Journal of Psychiatry*, **2016**, 61, 506-9	4.8	47
319	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. *Canadian Journal of Psychiatry*, **2016**, 61, 588-603	4.8	114
318	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. *Canadian Journal of Psychiatry*, **2016**, 61, 510-23	4.8	140
317	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. *Canadian Journal of Psychiatry*, **2016**, 61, 540-60	4.8	469
316	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments. *Canadian Journal of Psychiatry*, **2016**, 61, 524-39	4.8	160
315	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. *Canadian Journal of Psychiatry*, **2016**, 61, 561-75	4.8	270
314	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. *Canadian Journal of Psychiatry*, **2016**, 61, 576-87	4.8	146
313	Zebrafish models of major depressive disorders. *Journal of Neuroscience Research*, **2016**, 94, 3-14	4.4	35
312	The role of genetic variation across IL-1, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. *World Journal of Biological Psychiatry*, **2015**, 16, 45-56	3.8	26
311	Paired Pulse Depression in the Subcallosal Cingulate Region of Depression Patients. *Biological Psychiatry*, **2015**, 78, e3-e4	7.9	7
310	Deep Brain Stimulation Modulates Gamma Oscillations and Theta-Gamma Coupling in Treatment Resistant Depression. *Brain Stimulation*, **2015**, 8, 1033-42	5.1	27
309	Correlates of benzodiazepine use in major depressive disorder: The effect of anhedonia. *Journal of Affective Disorders*, **2015**, 187, 101-5	6.6	14
308	Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis. *JAMA Psychiatry*, **2015**, 72, 1102-9	14.5	117
307	Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression. *Psychiatry Research*, **2015**, 229, 109-19	9.9	60
306	Evidence to support peripheral and central IL-6 signaling targets to treat depression. *Expert Opinion on Investigational Drugs*, **2015**, 24, 991-2	5.9	1
305	Genetic variation in IL-1, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder. *Pharmacogenomics*, **2015**, 16, 1919-29	2.6	13
304	The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. *Comprehensive Psychiatry*, **2015**, 56, 279-82	7.3	94
303	The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project. *Journal of Affective Disorders*, **2015**, 172, 259-64	6.6	71

302	MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder. *Journal of Visualized Experiments*, **2015**, e53129	1.6	12
301	Depression and employment status in primary and tertiary care settings. *Canadian Journal of Psychiatry*, **2015**, 60, 14-22	4.8	43
300	rTMS of the dorsomedial prefrontal cortex for major depression: safety, tolerability, effectiveness, and outcome predictors for 10 Hz versus intermittent theta-burst stimulation. *Brain Stimulation*, **2015**, 8, 208-15	5.1	155
299	Novel investigational drugs targeting IL-6 signaling for the treatment of depression. *Expert Opinion on Investigational Drugs*, **2015**, 24, 459-75	5.9	35
298	Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. *Annals of Clinical Psychiatry*, **2015**, 27, 142-9	1.4	32
297	Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. *Biological Psychiatry*, **2014**, 76, 176-85	7.9	202
296	Neuromodulation for treatment-refractory major depressive disorder. *Cmaj*, **2014**, 186, 33-9	3.5	26
295	The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. *Psychiatry Research*, **2014**, 220, 245-50	9.9	37
294	Depression treatment by withdrawal of short-term low-dose antipsychotic, a proof-of-concept randomized double-blind study. *Journal of Affective Disorders*, **2014**, 166, 139-43	6.6	2
293	A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder. *European Neuropsychopharmacology*, **2014**, 24, 553-63	1.2	24
292	Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. *Canadian Journal of Psychiatry*, **2014**, 59, 649-54	4.8	189
291	Treatment-resistant depression in primary care across Canada. *Canadian Journal of Psychiatry*, **2014** , 59, 349-57	4.8	83
290	Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue. *Journal of Clinical Psychopharmacology*, **2014**, 34, 755-9	1.7	13
289	EEG power asymmetry and functional connectivity as a marker of treatment effectiveness in DBS surgery for depression. *Neuropsychopharmacology*, **2014**, 39, 1270-81	8.7	59
288	Resting-state cortico-thalamic-striatal connectivity predicts response to dorsomedial prefrontal rTMS in major depressive disorder. *Neuropsychopharmacology*, **2014**, 39, 488-98	8.7	173
287	Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: an "individual patient data" meta-analysis. *Depression and Anxiety*, **2014**, 31, 941-51	8.4	103
286	Review of evidence for use of antidepressants in bipolar depression. *primary care companion for CNS disorders, The*, **2014**, 16,	1.2	9
285	Agomelatine in Depressive Disorders **2014**, 275-279		

284	SSRIs and Related Compounds **2014**, 1-7		
283	The effect of personality dimensions on functional outcomes in mood disorders. *Advances in Therapy*, **2013**, 30, 671-83	4.1	3
282	Comments on the Use of Agomelatine in the Treatment of Depressive Disorder According to Clinical Guidelines in Colombia. *Revista Colombiana De Psiquiatría*, **2013**, 42, 356-7	0.8	
281	The cardiovascular safety profile of escitalopram. *European Neuropsychopharmacology*, **2013**, 23, 1391-400	2.2	35
280	The effect of vilazodone on sexual function during the treatment of major depressive disorder. *Journal of Sexual Medicine*, **2013**, 10, 2465-76	1.1	38
279	Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. *Journal of Affective Disorders*, **2013**, 151, 573-581	6.6	34
278	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. *Bipolar Disorders*, **2013**, 15, 1-44	3.8	583
277	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. *Bipolar Disorders*, **2013**, 15, 58-60	3.8	12
276	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated bipolar disorder guidelines. *Bipolar Disorders*, **2013**, 15, 338-9	3.8	1
275	Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. *Human Psychopharmacology*, **2013**, 28, 151-9	2.3	110
274	The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. *Human Psychopharmacology*, **2013**, 28, 421-7	2.3	16
273	Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. *British Journal of Psychiatry*, **2013**, 203, 358-65	5.4	33
272	Management strategies for SSRI-induced sexual dysfunction. *Journal of Psychiatry and Neuroscience* , **2013**, 38, E27-8	4.5	11
271	A review of antidepressant therapy in primary care: current practices and future directions. *primary care companion for CNS disorders, The*, **2013**, 15,	1.2	20
270	Childhood maltreatment and differential treatment response and recurrence in adult major depressive disorder. *Journal of Consulting and Clinical Psychology*, **2012**, 80, 342-53	6.5	67
269	Novel therapeutic targets in depression: minocycline as a candidate treatment. *Behavioural Brain Research*, **2012**, 235, 302-17	3.4	135
268	The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. *European Psychiatry*, **2012**, 27, 223-8	6	79
267	A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. *Bipolar Disorders*, **2012**, 14, 697-706	3.8	64

266	Admixture analysis of age at onset in major depressive disorder. *General Hospital Psychiatry*, **2012**, 34, 686-91	5.6	15
265	A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. *Journal of Neurosurgery*, **2012**, 116, 315-22	3.2	277
264	Monoamine oxidase inhibitors potentiate the effects of deep brain stimulation. *American Journal of Psychiatry*, **2012**, 169, 1320-1	11.9	11
263	The association between childhood adversity and components of metabolic syndrome in adults with mood disorders: results from the international mood disorders collaborative project. *International Journal of Psychiatry in Medicine*, **2012**, 43, 165-77	1	55
262	Melatonin receptor agonists/5-HT2Cantagonists **2012**, 82-92		
261	The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. *Current Pharmaceutical Design*, **2012**, 18, 5976-89	3.3	48
260	A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME]. *Journal of Clinical Psychiatry*, **2012**, 73, 803-10	4.6	85
259	Instruments to measure sexual dysfunction in community and psychiatric populations. *Journal of Psychosomatic Research*, **2011**, 70, 99-109	4.1	25
258	Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets. *Journal of Affective Disorders*, **2011**, 132 Suppl 1, S21-8	6.6	13
257	The keys to improving depression outcomes. *European Neuropsychopharmacology*, **2011**, 21 Suppl 4, S694-702	4.2	9
256	Weight Loss Following Roux-en-Y Gastric Bypass Surgery: A Systematic Review of Psychosocial Predictors. *Current Psychiatry Reviews*, **2011**, 7, 226-233	0.9	15
255	A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder. *International Clinical Psychopharmacology*, **2011**, 26, 151-8	2.2	13
254	Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. *British Journal of Psychiatry*, **2011**, 199, 501-7	5.4	51
253	Association of the malnutrition-inflammation score with clinical outcomes in kidney transplant recipients. *American Journal of Kidney Diseases*, **2011**, 58, 101-8	7.4	61
252	Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. *Journal of Affective Disorders*, **2011**, 132 Suppl 1, S14-20	6.6	18
251	Association between the Malnutrition-Inflammation Score and depressive symptoms in kidney transplanted patients. *General Hospital Psychiatry*, **2011**, 33, 157-65	5.6	26
250	Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. *NeuroMolecular Medicine*, **2011**, 13, 93-116	4.6	119
249	Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions. *Current Psychiatry Reports*, **2011**, 13, 316-20	9.1	44

248	The effects of agomelatine on sexual function in depressed patients and healthy volunteers. *Human Psychopharmacology*, **2011**, 26, 537-42	2.3	38
247	Neurostimulation therapies for treatment resistant depression: a focus on vagus nerve stimulation and deep brain stimulation. *International Review of Psychiatry*, **2011**, 23, 424-36	3.6	31
246	Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. *American Journal of Psychiatry*, **2011**, 168, 502-10	11.9	376
245	Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets. *Bipolar Disorders*, **2010**, 12, 691-701	3.8	19
244	Harm avoidance as a mediator of treatment response to antidepressant treatment of patients with major depression. *Psychotherapy and Psychosomatics*, **2010**, 79, 116-22	9.4	29
243	The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. *CNS Drugs*, **2010**, 24, 741-53	6.7	57
242	The Nature and Treatment of Therapy-Resistant Depression. *Modern Problems of Pharmacopsychiatry*, **2010**, 243-253		
241	Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. *CNS Drugs*, **2010**, 24, 479-99	6.7	98
240	Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials. *Current Medical Research and Opinion*, **2010**, 26, 2643-51	2.5	5
239	Omega-3 supplements in pregnancy: are we too late to identify the possible benefits?. *Journal of Obstetrics and Gynaecology Canada*, **2010**, 32, 209-16	1.3	1
238	Using Metaanalysis to Evaluate Evidence: Practical Tips and Traps. *Focus (American Psychiatric Publishing)*, **2010**, 8, 151-158	1.1	
237	A comparison of desipramine response in younger and older women. *Journal of Clinical Psychopharmacology*, **2010**, 30, 80-2	1.7	2
236	Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder. *Canadian Journal of Psychiatry*, **2010**, 55, 568-76	4.8	39
235	Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders?. *Advances in Therapy*, **2010**, 27, 63-80	4.1	57
234	The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. *Advances in Therapy*, **2010**, 27, 828-36	4.1	28
233	The relationship between testosterone and sexual function in depressed and healthy men. *Journal of Sexual Medicine*, **2010**, 7, 816-25	1.1	31
232	Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. *Journal of Sexual Medicine*, **2010**, 7, 3449-59	1.1	36
231	Attention-deficit/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the international mood disorders collaborative project. *Primary Care Companion To the Journal of Clinical Psychiatry*, **2010**, 12,		38

230	Subgenual Cingulate Gyrus Deep Brain Stimulation: Current Status and Future Directions. *Psychiatric Annals*, **2010**, 40, 485-491	0.5	1
229	The sex effects scale: pilot validation in a healthy population. *Psychopharmacology Bulletin*, **2010**, 43, 15-25	0.9	12
228	Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin. *Evidence-Based Mental Health*, **2010**, 13, 89	11.1	
227	Desvenlafaxine in the treatment of major depressive disorder. *Neuropsychiatric Disease and Treatment*, **2009**, 5, 127-36	3.1	12
226	Perceptions of efficacy, safety, and tolerability: impact on evaluating new treatments. *CNS Spectrums*, **2009**, 14, 8-10	1.8	
225	Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. *Expert Opinion on Pharmacotherapy*, **2009**, 10, 3061-75	4	26
224	Emerging drugs for major depressive disorder. *Expert Opinion on Emerging Drugs*, **2009**, 14, 439-53	3.7	24
223	Deep brain stimulation of the subcallosal cingulate gyrus for depression: anatomical location of active contacts in clinical responders and a suggested guideline for targeting. *Journal of Neurosurgery*, **2009**, 111, 1209-15	3.2	130
222	Sex differences in hormonal responses to a social stressor in chronic major depression. *Psychoneuroendocrinology*, **2009**, 34, 1235-41	5	59
221	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. *Journal of Affective Disorders*, **2009**, 117 Suppl 1, S44-53	6.6	140
220	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. *Journal of Affective Disorders*, **2009**, 117 Suppl 1, S54-64	6.6	75
219	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. *Journal of Affective Disorders*, **2009**, 117 Suppl 1, S26-43	6.6	298
218	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. *Journal of Affective Disorders*, **2009**, 117 Suppl 1, S15-25	6.6	125
217	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. *Journal of Affective Disorders*, **2009**, 117 Suppl 1, S1-2	6.6	114
216	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. *Journal of Affective Disorders*, **2009**, 117 Suppl 1, S5-14	6.6	105
215	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. *Bipolar Disorders*, **2009**, 11, 225-55	3.8	465
214	CANMAT guidelines: authors response. *Bipolar Disorders*, **2009**, 11, 773-773	3.8	
213	CANMAT/ ISBD treatment guidelines: response to Shen et´al.. *Bipolar Disorders*, **2009**, 11, 775-775	3.8	

212	The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?. *NeuroToxicology*, **2009**, 30, 497-521	4.4	75
211	Escitalopram in the treatment of major depressive disorder: a meta-analysis. *Current Medical Research and Opinion*, **2009**, 25, 161-75	2.5	100
210	Agomelatine: efficacy at each phase of antidepressant treatment. *CNS Drugs*, **2009**, 23 Suppl 2, 41-7	6.7	17
209	Sexual dysfunction, depression, and the impact of antidepressants. *Journal of Clinical Psychopharmacology*, **2009**, 29, 157-64	1.7	212
208	Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. *Journal of Psychiatry and Neuroscience*, **2009**, 34, 175-80	4.5	87
207	A novel examination of atypical major depressive disorder based on attachment theory. *Journal of Clinical Psychiatry*, **2009**, 70, 879-87	4.6	18
206	Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. *Bipolar Disorders*, **2008**, 10, 1-37	3.8	222
205	Dimensional personality traits and treatment outcome in patients with major depressive disorder. *Journal of Affective Disorders*, **2008**, 108, 241-50	6.6	112
204	Investigating associations between cortisol and cognitive reactivity to sad mood provocation and the prediction of relapse in remitted major depression. *Asian Journal of Psychiatry*, **2008**, 1, 33-6	6.7	13
203	Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. *Biological Psychiatry*, **2008**, 64, 461-7	7.9	731
202	The relationship between childhood abuse and suicidality in adult bipolar disorder. *Violence and Victims*, **2008**, 23, 361-72	1.1	47
201	The hepatic safety profile of duloxetine: a review. *Expert Opinion on Drug Metabolism and Toxicology*, **2008**, 4, 281-5	5.5	36
200	Deep Brain Stimulation for Treatment-Resistant Depression. *Focus (American Psychiatric Publishing)*, **2008**, 6, 143-154	1.1	2
199	Neural stimulation successfully treats depression in patients with prior ablative cingulotomy. *American Journal of Psychiatry*, **2008**, 165, 687-93	11.9	49
198	Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders?. *Expert Opinion on Investigational Drugs*, **2008**, 17, 827-43	5.9	15
197	A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. *Journal of Clinical Psychopharmacology*, **2008**, 28, 329-33	1.7	151
196	Rates and patterns of treatment seeking by individuals with mood and anxiety disorders. *Psychiatric Services*, **2008**, 59, 1099	3.3	1
195	Neuropsychological impact of Cg25 deep brain stimulation for treatment-resistant depression: preliminary results over 12 months. *Journal of Nervous and Mental Disease*, **2008**, 196, 405-10	1.8	111

194	Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function. *Journal of Clinical Psychopharmacology*, **2008**, 28, 107-8	1.7	13
193	Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. *Canadian Journal of Psychiatry*, **2008**, 53, 361-70	4.8	117
192	Core symptoms of major depressive disorder: relevance to diagnosis and treatment. *Dialogues in Clinical Neuroscience*, **2008**, 10, 271-7	5.7	136
191	Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. *Journal of Clinical Psychiatry*, **2008**, 69, 87-94	4.6	86
190	Agomelatine: an antidepressant with a novel mechanism of action. *Future Neurology*, **2007**, 2, 145-151	1.5	7
189	Are antidepressants as effective as claimed? Yes, but. *Canadian Journal of Psychiatry*, **2007**, 52, 98-9; discussion 100-1	4.8	4
188	Screening for mental health problems among patients with substance use disorders: preliminary findings on the validation of a self-assessment instrument. *Canadian Journal of Psychiatry*, **2007**, 52, 22-7	4.8	11
187	Measuring depressive symptoms in the naturalistic primary-care setting. *International Journal of Clinical Practice*, **2007**, 61, 1278-82	2.9	2
186	Problem gambling in bipolar disorder: results from the Canadian Community Health Survey. *Journal of Affective Disorders*, **2007**, 102, 27-34	6.6	40
185	Relationship between regional brain metabolism, illness severity and age in depressed subjects. *Psychiatry Research - Neuroimaging*, **2007**, 155, 203-10	2.9	39
184	Neuroimaging approaches in mood disorders: technique and clinical implications. *Annals of Clinical Psychiatry*, **2007**, 19, 265-77	1.4	25
183	Review: response to SSRIs in unipolar depression occurs in the first week of treatment. *Evidence-Based Mental Health*, **2007**, 10, 81	11.1	
182	Comparing features of bipolar disorder to major depressive disorder in a tertiary mood disorders clinic. *Annals of Clinical Psychiatry*, **2007**, 19, 313-7	1.4	11
181	Treatment resistant depression--advances in somatic therapies. *Annals of Clinical Psychiatry*, **2007**, 19, 279-87	1.4	58
180	Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. *American Journal of Psychiatry*, **2007**, 164, 778-88	11.9	314
179	Changes in autobiographical memory specificity following cognitive behavior therapy and pharmacotherapy for major depression. *Psychopathology*, **2007**, 40, 147-52	3.4	57
178	Relationship of posttreatment decentering and cognitive reactivity to relapse in major depression. *Journal of Consulting and Clinical Psychology*, **2007**, 75, 447-55	6.5	186
177	Response to Dr Moncrieff. *Canadian Journal of Psychiatry*, **2007**, 52, 102-102	4.8	1

176	Residual anxiety symptoms in depressed primary care patients. *Journal of Psychiatric Practice*, **2007**, 13, 125-8	1.3	6
175	Sex differences in antidepressant response in a Canadian primary-care sample. *Journal of Clinical Psychopharmacology*, **2007**, 27, 95-8	1.7	3
174	Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. *Current Opinion in Psychiatry*, **2007**, 20, 406-16	4.9	95
173	Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?. *Expert Opinion on Pharmacotherapy*, **2007**, 8, 1615-28	4	27
172	Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?. *Annals of Clinical Psychiatry*, **2007**, 19, 257-64	1.4	180
171	Agomelatine and its therapeutic potential in the depressed patient. *Neuropsychiatric Disease and Treatment*, **2007**, 3, 423-8	3.1	11
170	Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. *Journal of Clinical Psychiatry*, **2007**, 68, 1352-7	4.6	54
169	Deep brain stimulation for treatment-resistant depression: a psychiatric perspective. *Current Psychiatry Reports*, **2006**, 8, 437-44	9.1	28
168	Validation of an IVRS version of the MADRS. *Journal of Psychiatric Research*, **2006**, 40, 243-6	5.2	29
167	Calculated bioavailable testosterone levels and depression in middle-aged men. *Psychoneuroendocrinology*, **2006**, 31, 1029-35	5	85
166	Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. *Archives of General Psychiatry*, **2006**, 63, 749-55		313
165	Current treatment options: relief of symptoms and ultimate recovery. *International Journal of Psychiatry in Clinical Practice*, **2006**, 10 Suppl 1, 22-6	2.4	
164	Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. *Psychiatric Services*, **2006**, 57, 1140-4	3.3	148
163	The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. *Expert Opinion on Drug Safety*, **2006**, 5, 157-68	4.1	159
162	The effect of antidepressants on lipid homeostasis: a cardiac safety concern?. *Expert Opinion on Drug Safety*, **2006**, 5, 523-37	4.1	52
161	A review of antidepressant treatments today. *European Neuropsychopharmacology*, **2006**, 16, S619-S623	1.2	43
160	Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. *Expert Opinion on Pharmacotherapy*, **2006**, 7, 1305-21	4	19
159	Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. *European Neuropsychopharmacology*, **2006**, 16, 93-100	1.2	226

158	Improving outcomes in depression: a focus on somatic symptoms. *Journal of Psychosomatic Research*, **2006**, 60, 279-82	4.1	41
157	Sexual function during bupropion or paroxetine treatment of major depressive disorder. *Canadian Journal of Psychiatry*, **2006**, 51, 234-42	4.8	61
156	Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. *Canadian Journal of Psychiatry*, **2006**, 51, 274-80	4.8	111
155	Anxiety disorders and bipolar disorder: a review. *Bipolar Disorders*, **2006**, 8, 665-76	3.8	71
154	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. *Bipolar Disorders*, **2006**, 8, 721-39	3.8	168
153	The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. *Headache*, **2006**, 46, 973-82	4.2	92
152	Treatment guidelines for mania. *Journal of Psychiatry and Neuroscience*, **2006**, 31, 144	4.5	
151	Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. *Journal of Psychiatry and Neuroscience*, **2006**, 31, 122-31	4.5	110
150	Clinical translation of neuroimaging research in mood disorders. *Psychiatry*, **2006**, 3, 46-57		2
149	Deep brain stimulation for treatment-resistant depression. *Neuron*, **2005**, 45, 651-60	13.9	2899
148	A dimensional approach to personality in atypical depression. *Psychiatry Research*, **2005**, 134, 161-7	9.9	12
147	Antidepressant augmentation with raloxifene. *Journal of Clinical Psychopharmacology*, **2005**, 25, 96-8	1.7	9
146	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. *Bipolar Disorders*, **2005**, 7 Suppl 3, 5-69	3.8	274
145	Using metaanalysis to evaluate evidence: practical tips and traps. *Canadian Journal of Psychiatry*, **2005**, 50, 167-74	4.8	39
144	Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. *Annals of Clinical Psychiatry*, **2005**, 17, 83-93	1.4	160
143	Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. *Cmaj*, **2005**, 173, 1327-34	3.5	95
142	Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. *Cmaj*, **2005**, 172, 57-9	3.5	38
141	Simulator Performance vs. Neurophysiologic Monitoring: Which is More Relevant to Assess Driving Impairment? **2005**,		2

140	The effects of nefazodone on women with seasonal affective disorder: clinical and polysomnographic analyses. *Journal of Psychiatry and Neuroscience*, **2005**, 30, 11-6	4.5	10
139	Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?. *Journal of Psychiatry and Neuroscience*, **2005**, 30, 178-86	4.5	156
138	Mental health and mental illness in the workplace: diagnostic and treatment issues. *HealthcarePapers*, **2004**, 5, 54-67	0.7	10
137	Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. *Archives of General Psychiatry*, **2004**, 61, 34-41		788
136	The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. *Biological Psychiatry*, **2004**, 56, 665-9	7.9	84
135	Childhood inattention and dysphoria and adult obesity associated with the dopamine D4 receptor gene in overeating women with seasonal affective disorder. *Neuropsychopharmacology*, **2004**, 29, 179-86	8.7	79
134	Limbic-frontal circuitry in major depression: a path modeling metanalysis. *NeuroImage*, **2004**, 22, 409-18	7.9	603
133	Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. *International Clinical Psychopharmacology*, **2004**, 19, 271-80	2.2	151
132	The 5-factor model of personality and antidepressant medication compliance. *Canadian Journal of Psychiatry*, **2004**, 49, 106-13	4.8	37
131	Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. *Canadian Journal of Psychiatry*, **2004**, 49, 17S-26S	4.8	19
130	Antipsychotic-induced weight gain: bipolar disorder and leptin. *Journal of Clinical Psychopharmacology*, **2003**, 23, 323-7	1.7	37
129	A comparison of antidepressant response in younger and older women. *Journal of Clinical Psychopharmacology*, **2003**, 23, 405-7	1.7	43
128	Valproate, bipolar disorder and polycystic ovarian syndrome. *Bipolar Disorders*, **2003**, 5, 28-35	3.8	85
127	Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. *Bipolar Disorders*, **2003**, 5 Suppl 2, 36-47	3.8	85
126	State and trait influences on mood regulation in bipolar disorder: blood flow differences with an acute mood challenge. *Biological Psychiatry*, **2003**, 54, 1274-83	7.9	116
125	Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. *American Journal of Psychiatry*, **2003**, 160, 90-9	11.9	218
124	Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. *Expert Opinion on Investigational Drugs*, **2003**, 12, 65-86	5.9	19
123	Clinical guidelines for depressive disorders. Summary of recommendations relevant to family physicians. *Canadian Family Physician*, **2003**, 49, 489-91	0.9	9

122	Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. *Journal of Clinical Psychiatry*, **2003**, 64, 439-44	4.6	19
121	EEG correlates of acute and chronic paroxetine treatment in depression. *Journal of Affective Disorders*, **2002**, 69, 241-9	6.6	38
120	Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. *Journal of Affective Disorders*, **2002**, 71, 229-33	6.6	65
119	Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. *Bipolar Disorders*, **2002**, 4, 207-13	3.8	123
118	Role of estrogen in the treatment of depression. *American Journal of Therapeutics*, **2002**, 9, 503-9	1	47
117	Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. *Canadian Journal of Psychiatry*, **2002**, 47, 174-80	4.8	83
116	Low-dose dexamethasone challenge in women with atypical major depression: pilot study. *Journal of Psychiatry and Neuroscience*, **2002**, 27, 47-51	4.5	43
115	Full remission: a return to normal functioning. *Journal of Psychiatry and Neuroscience*, **2002**, 27, 233-4	4.5	15
114	Assessing full remission. *Journal of Psychiatry and Neuroscience*, **2002**, 27, 235-9	4.5	65
113	Prevalence and outcome of partial remission in depression. *Journal of Psychiatry and Neuroscience*, **2002**, 27, 241-7	4.5	71
112	Pharmacotherapy to sustain the fully remitted state. *Journal of Psychiatry and Neuroscience*, **2002**, 27, 269-80	4.5	36
111	Reboxetine: a preliminary report on its use through the Special Access Program. *Journal of Psychiatry and Neuroscience*, **2002**, 27, 418-22	4.5	3
110	Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. *Journal of Clinical Psychiatry*, **2002**, 63, 181-6	4.6	96
109	Combining antidepressants for treatment-resistant depression: a review. *Journal of Clinical Psychiatry*, **2002**, 63, 685-93	4.6	86
108	Mood-induced changes on the Implicit Association Test in recovered depressed patients.. *Journal of Abnormal Psychology*, **2001**, 110, 282-289	7	168
107	Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. *Canadian Journal of Psychiatry*, **2001**, 46, 273-81	4.8	181
106	Lower dopamine transporter binding potential in striatum during depression. *NeuroReport*, **2001**, 12, 4121-5	1.7	217
105	Antidepressants in clinical practice: limitations of assessment methods and drug response. *Human Psychopharmacology*, **2001**, 16, 105-114	2.3	25

104	The Stability and Validity of the Sociotropy and Autonomy Personality Dimensions as Measured by the Revised Personal Style Inventory. *Cognitive Therapy and Research*, **2001**, 25, 765-779	2.7	35
103	Comparisons of men with full or partial eating disorders, men without eating disorders, and women with eating disorders in the community. *American Journal of Psychiatry*, **2001**, 158, 570-4	11.9	212
102	The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. *American Journal of Psychiatry*, **2001**, 158, 78-85	11.9	189
101	Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. *American Journal of Psychiatry*, **2001**, 158, 899-905	11.9	556
100	Noradrenergic dysfunction in the prefrontal cortex in depression: an [15O] H2O PET study of the neuromodulatory effects of clonidine. *Biological Psychiatry*, **2001**, 49, 317-25	7.9	32
99	Polymorphism of the serotonin 5-HT1B receptor gene (HTR1B) associated with minimum lifetime body mass index in women with bulimia nervosa. *Biological Psychiatry*, **2001**, 50, 640-3	7.9	47
98	EEG power, frequency, asymmetry and coherence in male depression. *Psychiatry Research - Neuroimaging*, **2001**, 106, 123-40	2.9	235
97	Lithium revisited. *Canadian Journal of Psychiatry*, **2001**, 46, 322-7	4.8	25
96	Suicidal ideation in major depression: sex differences and impact of comorbid anxiety. *Canadian Journal of Psychiatry*, **2000**, 45, 822-6	4.8	41
95	Differentiating DSM-IV anxiety and depressive disorders in the general population: comorbidity and treatment consequences. *Canadian Journal of Psychiatry*, **2000**, 45, 166-72	4.8	60
94	Determination of paroxetine levels in human plasma using gas chromatography with electron-capture detection. *Biomedical Applications*, **2000**, 749, 275-9		18
93	Neurohormonal responses to D-fenfluramine in healthy elderly subjects. A placebo-controlled study. *Psychoneuroendocrinology*, **2000**, 25, 139-50	5	7
92	Pre-treatment EEG and it's relationship to depression severity and paroxetine treatment outcome. *Pharmacopsychiatry*, **2000**, 33, 201-5	2	96
91	Increased left posterior parietal-temporal cortex activation after D-fenfluramine in women with panic disorder. *Psychiatry Research - Neuroimaging*, **2000**, 98, 133-43	2.9	24
90	Medication compliance in mood disorders relevance of the Health Belief Model and other determinants. *Primary Care and Community Psychiatry*, **2000**, 6, 101-110		15
89	Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. *Journal of Clinical Psychiatry*, **2000**, 61, 276-81	4.6	149
88	Tolerability and efficacy of high-dose moclobemide alone and in combination with lithium and trazodone. *Journal of Clinical Psychopharmacology*, **2000**, 20, 394-5	1.7	2
87	The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET. *Psychopharmacology*, **1999**, 144, 279-81	4.7	34

86	A neuroendocrine study of serotonin function in depressed stroke patients compared to non depressed stroke patients and healthy controls. *Journal of Affective Disorders*, **1999**, 52, 121-33	6.6	10
85	Depression in Ontario: under-treatment and factors related to antidepressant use. *Journal of Affective Disorders*, **1999**, 52, 67-76	6.6	32
84	Rumination and distraction in major depression: assessing response to pharmacological treatment. *Journal of Affective Disorders*, **1999**, 55, 225-9	6.6	41
83	Sexual dysfunction before antidepressant therapy in major depression. *Journal of Affective Disorders*, **1999**, 56, 201-8	6.6	325
82	Clinical aspects of depression. *Clinical Cornerstone*, **1999**, 1, 1-16		2
81	Elevated plasma lipids in patients with binge eating disorders are found only in those who are anorexic. *International Journal of Eating Disorders*, **1999**, 25, 187-93	6.3	25
80	Sequencing of cognitive-behavioral treatments for bulimia nervosa. *International Journal of Eating Disorders*, **1999**, 25, 361-74	6.3	33
79	Selective alteration of personality in response to noradrenergic and serotonergic antidepressant medication in depressed sample: evidence of non-specificity. *Psychiatry Research*, **1999**, 86, 211-6	9.9	38
78	Replicating the five factor model of personality in a psychiatric sample. *Personality and Individual Differences*, **1999**, 27, 1135-1139	3.3	63
77	Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. *Biological Psychiatry*, **1999**, 45, 872-82	7.9	120
76	. *Cellular and Molecular Neurobiology*, **1999**, 19, 411-426	4.6	46
75	The changing profile of anorexia nervosa at the Toronto Programme for Eating Disorders. *Journal of Psychosomatic Research*, **1998**, 45, 533-47	4.1	8
74	Major depression in individuals with a history of childhood physical or sexual abuse: relationship to neurovegetative features, mania, and gender. *American Journal of Psychiatry*, **1998**, 155, 1746-52	11.9	149
73	Diminished serotonin-mediated prolactin responses in nondepressed stroke patients compared with healthy normal subjects. *Stroke*, **1998**, 29, 1293-8	6.7	18
72	Self-report ratings and informants' ratings of personalities of depressed outpatients. *American Journal of Psychiatry*, **1998**, 155, 437-8	11.9	67
71	No effect of depression on [(15)O]H2O PET response to intravenous d-fenfluramine. *American Journal of Psychiatry*, **1998**, 155, 1241-6	11.9	32
70	A randomized controlled trial of guided imagery in bulimia nervosa. *Psychological Medicine*, **1998**, 28, 1347-57	6.9	38
69	Hormonal and subjective responses to intravenous m-chlorophenylpiperazine in women with seasonal affective disorder. *Archives of General Psychiatry*, **1998**, 55, 244-9		24

68	Reversed neurovegetative symptoms of depression: a community study of Ontario. *American Journal of Psychiatry*, **1997**, 154, 934-40	11.9	77
67	Depressive symptoms and alterations in sucrose taste perception: cognitive bias or a true change in sensitivity?. *Canadian Journal of Experimental Psychology*, **1997**, 51, 57-60	0.8	17
66	A review of functional neuroimaging in mood disorders: positron emission tomography and depression. *Canadian Journal of Psychiatry*, **1997**, 42, 467-75	4.8	100
65	Personality factors related to the prevalence of somatic symptoms and medical complaints in a healthy student population. *The British Journal of Medical Psychology*, **1997**, 70 (Pt 1), 93-101		35
64	Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression. *Biological Psychiatry*, **1997**, 41, 366-8	7.9	18
63	Personality and symptom profiles of the angry hostile depressed patient. *Journal of Affective Disorders*, **1997**, 45, 155-60	6.6	16
62	Differential pharmacological treatment response in high angry hostile and low angry hostile depressed patients: a retrospective analysis. *Journal of Affective Disorders*, **1997**, 45, 161-6	6.6	9
61	Sociotropy, Autonomy, and Patterns of Symptoms in Patients with Major Depression: A Comparison of Dimensional and Categorical Approaches. *Cognitive Therapy and Research*, **1997**, 21, 285-300	2.7	50
60	The effects of moclobemide on sexual desire and function in healthy volunteers. *European Neuropsychopharmacology*, **1996**, 6, 177-81	1.2	15
59	Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. *Psychiatry Research*, **1996**, 63, 219-22	9.9	96
58	Purging and nonpurging forms of bulimia nervosa in a community sample. *International Journal of Eating Disorders*, **1996**, 20, 231-8	6.3	33
57	Exposure with response prevention treatment of anorexia nervosa-bulimic subtype and bulimia nervosa. *Behaviour Research and Therapy*, **1995**, 33, 685-9	5.2	21
56	Obsessive compulsiveness and physical activity in anorexia nervosa and high-level exercising. *Journal of Psychosomatic Research*, **1995**, 39, 967-76	4.1	89
55	Bulimia nervosa in a Canadian community sample: prevalence and comparison of subgroups. *American Journal of Psychiatry*, **1995**, 152, 1052-8	11.9	372
54	Assessment of personality disorders in anorexia nervosa and bulimia nervosa. A comparison of self-report and structured interview methods. *Journal of Nervous and Mental Disease*, **1995**, 183, 358-64	1.8	16
53	Views on classification and diagnosis of eating disorders. *Canadian Journal of Psychiatry*, **1995**, 40, 445-56	4.8	50
52	The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers. *Journal of Clinical Psychopharmacology*, **1995**, 15, 347-52	1.7	44
51	The role of physical activity in the development and maintenance of eating disorders. *Psychological Medicine*, **1994**, 24, 957-67	6.9	227

50	Melatonin disturbances in anorexia nervosa and bulimia nervosa. *International Journal of Eating Disorders*, **1994**, 16, 257-65	6.3	11
49	Therapeutic alliance on an inpatient unit for eating disorders. *International Journal of Eating Disorders*, **1994**, 16, 405-10	6.3	30
48	The effects of growth hormone-releasing factor on food consumption in anorexia nervosa patients and normals. *Biological Psychiatry*, **1994**, 35, 446-51	7.9	13
47	Depression in anorexia nervosa and bulimia nervosa: discriminating depressive symptoms and episodes. *Journal of Psychosomatic Research*, **1994**, 38, 773-82	4.1	60
46	A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. *Journal of Affective Disorders*, **1994**, 32, 105-14	6.6	14
45	Advances in the Treatment of Anorexia Nervosa and Bulimia Nervosa. *CNS Drugs*, **1994**, 1, 201-12	6.7	1
44	Changes in perceptions and emotions before and after refeeding in anorexia nervosa: a pilot study. *Irish Journal of Psychological Medicine*, **1994**, 11, 57-63	3	3
43	Factors complicating the diagnosis of depression in cerebrovascular disease, Part II--Neurological deficits and various assessment methods. *Canadian Journal of Psychiatry*, **1994**, 39, 601-7	4.8	10
42	Factors complicating the diagnosis of depression in cerebrovascular disease, Part I--Phenomenological and nosological issues. *Canadian Journal of Psychiatry*, **1994**, 39, 596-600	4.8	13
41	The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **1993**, 17, 747-63	5.5	4
40	Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa. *Neurochemical Research*, **1993**, 18, 1281-5	4.6	3
39	The acute effects of starvation on 6-sulphatoxy-melatonin output in subgroups of patients with anorexia nervosa. *Psychoneuroendocrinology*, **1993**, 18, 131-9	5	9
38	Advances in diagnosis and treatment of anorexia nervosa and bulimia nervosa. *Canadian Journal of Psychiatry*, **1992**, 37, 309-15	4.8	14
37	Correlates of sexual abuse in women with anorexia nervosa and bulimia nervosa. *Canadian Journal of Psychiatry*, **1992**, 37, 516-8	4.8	21
36	Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. *Psychiatry Research*, **1992**, 43, 177-85	9.9	19
35	Post-residency fellowship training. *Canadian Journal of Psychiatry*, **1991**, 36, 151-2	4.8	1
34	Tryptophan treatment and melatonin response in a patient with seasonal affective disorder. *Journal of Clinical Psychopharmacology*, **1991**, 11, 74-5	1.7	10
33	A comparison of adinazolam and desipramine in the treatment of major depression. *International Clinical Psychopharmacology*, **1991**, 6, 65-76	2.2	5

32	Graves' disease in a woman with thyroid hormone abuse, bulimia nervosa, and a history of anorexia nervosa. *International Journal of Eating Disorders*, **1991**, 10, 111-115	6.3	7
31	Mitral valve prolapse in eating and panic disorder: A pilot study. *International Journal of Eating Disorders*, **1991**, 10, 531-537	6.3	3
30	Current perspectives on drug therapies for anorexia nervosa and bulimia nervosa. *Drugs*, **1991**, 41, 367-77	12.1	20
29	Pineal and adrenal function before and after refeeding in anorexia nervosa. *Biological Psychiatry*, **1991**, 30, 216-24	7.9	20
28	Self-report symptoms that predict major depression in patients with prominent physical symptoms. *International Journal of Psychiatry in Medicine*, **1990**, 20, 247-58	1	16
27	Sulphatoxy melatonin: an index of depression in anorexia nervosa and bulimia nervosa. *Psychiatry Research*, **1990**, 32, 221-7	9.9	21
26	Personality disorders in anorexia nervosa and bulimia nervosa. *Journal of Psychiatric Research*, **1990** , 24, 259-69	5.2	56
25	Changes in melatonin levels but not cortisol levels are associated with depression in patients with eating disorders. *Archives of General Psychiatry*, **1989**, 46, 73-8		49
24	Patients admitted to hospital with anorexia nervosa and bulimia nervosa: Psychopathology, weight gain, and attitudes toward treatment. *International Journal of Eating Disorders*, **1989**, 8, 181-190	6.3	9
23	Cardiac regulation in bulimia nervosa. *Journal of Psychiatric Research*, **1989**, 23, 267-73	5.2	21
22	Melatonin and cortisol "switches" during mania, depression, and euthymia in a drug-free bipolar patient. *Journal of Nervous and Mental Disease*, **1989**, 177, 300-3	1.8	48
21	Clonazepam and lithium--a toxic combination in the treatment of mania?. *International Clinical Psychopharmacology*, **1989**, 4, 195-9	2.2	8
20	Depression in self-harm patients. *British Journal of Psychiatry*, **1989**, 154, 41-7	5.4	38
19	The clinician-investigator interface in psychiatry I--Values and problems. *Canadian Journal of Psychiatry*, **1989**, 34, 361-3	4.8	12
18	Measured weight loss and the dexamethasone suppression test. *Canadian Journal of Psychiatry*, **1989**, 34, 707-9	4.8	2
17	The clinician-investigator interface in psychiatry: II--The role of the Clinical Investigation Unit. *Canadian Journal of Psychiatry*, **1989**, 34, 364-8	4.8	7
16	Pharmacological management of refractory depression. *Canadian Journal of Psychiatry*, **1989**, 34, 451-6	4.8	5
15	Psychiatry in Canada. *Psychiatric Bulletin*, **1989**, 13, 370-372		

14	Personality disorders in anorexic patients. *International Journal of Eating Disorders*, **1988**, 7, 589-599	6.3	83
13	A Trial of Isocarboxazid in the Treatment of Bulimia Nervosa. *Journal of Clinical Psychopharmacology*, **1988**, 8, 391???396	1.7	44
12	The diagnosis of major depression in renal dialysis patients. *Psychosomatic Medicine*, **1987**, 49, 482-92	3.7	100
11	The dexamethasone suppression test and suicidal patients. *British Journal of Psychiatry*, **1985**, 147, 419-23	5.4	13
10	Monoamine oxidase inhibitor therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid. *Journal of Clinical Psychopharmacology*, **1985**, 5, 279-85	1.7	28
9	Risk factors for depression in Canadians. *Canadian Journal of Psychiatry*, **1984**, 29, 11-3	4.8	2
8	Depression in chronic schizophrenia. *British Journal of Psychiatry*, **1983**, 142, 465-70	5.4	101
7	Life events precipitating mania. *British Journal of Psychiatry*, **1983**, 142, 398-403	5.4	97
6	Visual QC Protocol for FreeSurfer Cortical Parcellations from Anatomical MRI		1
5	Further Integration of Patient, Provider, and Systems Treatment Approaches in Bipolar Disorder: Where New Evidence Meets Practice Reality343-360		
4	Cognition and biomarkers in major depressive disorder: endophenotype or epiphenomenon?145-159		1
3	Baseline functional connectivity in resting state networks associated with depression and remission status after 16 weeks of pharmacotherapy: A CAN-BIND Report		1
2	Neuron-derived extracellular vesicles extracted from plasma show altered size and miRNA cargo as a function of antidepressant drug response		1
1	Integration of Patient, Provider, and Systems Treatment Approaches in Bipolar Disorder: Where Evidence Meets Practice Reality247-257		5